• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights.

作者信息

Chesnay Adélaïde, Bailly Éric, Cosson Laure, Flament Thomas, Desoubeaux Guillaume

机构信息

Parasitologie-Mycologie-Médecine Tropicale, Pôle Biologie Médicale, Hôpital Bretonneau, CHRU de, Tours 37044, France; Centre d'Etude des Pathologies Respiratoires, Inserm UMR1100, Faculté de Médecine, Université de Tours, 37032, France.

Parasitologie-Mycologie-Médecine Tropicale, Pôle Biologie Médicale, Hôpital Bretonneau, CHRU de, Tours 37044, France.

出版信息

J Cyst Fibros. 2022 Nov;21(6):1084-1085. doi: 10.1016/j.jcf.2022.09.007. Epub 2022 Sep 21.

DOI:10.1016/j.jcf.2022.09.007
PMID:36151024
Abstract
摘要

相似文献

1
Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights.用于治疗囊性纤维化的依列卡福/替扎卡福/艾伐卡福的出现：对曲霉相关疾病有何影响？初步见解。
J Cyst Fibros. 2022 Nov;21(6):1084-1085. doi: 10.1016/j.jcf.2022.09.007. Epub 2022 Sep 21.
2
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
3
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
4
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
5
Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor.接受依列卡福妥/替扎卡福妥/依伐卡福妥治疗的囊性纤维化患者的高胆红素血症和吉尔伯特综合征
J Cyst Fibros. 2023 Nov;22(6):1130-1132. doi: 10.1016/j.jcf.2023.06.013. Epub 2023 Jul 1.
6
Regarding the article entitled "Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis".关于题为《依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者肺功能年下降率的影响》的文章。
J Cyst Fibros. 2023 May;22(3):587. doi: 10.1016/j.jcf.2023.03.012. Epub 2023 Mar 21.
7
Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.依洛尤单抗治疗伴有实体器官移植的囊性纤维化患者的疗效。
Pediatr Pulmonol. 2023 Feb;58(2):602-605. doi: 10.1002/ppul.26217. Epub 2022 Nov 11.
8
Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis.研究信函：依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者雾化维持治疗依从性的影响
J Cyst Fibros. 2022 Nov;21(6):1080-1081. doi: 10.1016/j.jcf.2022.05.005. Epub 2022 May 16.
9
Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis.依列卡福妥/替扎卡福妥/依伐卡托治疗可减轻囊性纤维化患者的气道炎症。
Pediatr Pulmonol. 2023 May;58(5):1592-1594. doi: 10.1002/ppul.26334. Epub 2023 Feb 13.
10
Elexacaftor/Ivacaftor/Tezacaftor: First Approval.依伐卡托/埃乐卡福特/泰泽卡福特：首次批准。
Drugs. 2019 Dec;79(18):2001-2007. doi: 10.1007/s40265-019-01233-7.

引用本文的文献

1
Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on growth.依列卡福妥/替扎卡福妥/依伐卡托（三联疗法）对生长的条件依赖性影响
Microbiol Spectr. 2025 Sep 2;13(9):e0227524. doi: 10.1128/spectrum.02275-24. Epub 2025 Jul 30.
2
in Children and Young People with Cystic Fibrosis: A Narrative Review.针对患有囊性纤维化的儿童和青少年：一项叙述性综述。
J Fungi (Basel). 2025 Mar 9;11(3):210. doi: 10.3390/jof11030210.
3
Longitudinal Study on Clinical Predictors for Allergic Bronchopulmonary Aspergillosis in Children and Young People with Cystic Fibrosis Highlights the Impact of Infection with and and Ivacaftor Treatment.
关于囊性纤维化儿童和青少年过敏性支气管肺曲霉病临床预测指标的纵向研究凸显了感染[未提及具体感染物]以及依伐卡托治疗的影响。
J Fungi (Basel). 2025 Feb 4;11(2):116. doi: 10.3390/jof11020116.
4
Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.在患有囊性纤维化且有烟曲霉感染史的患者中，接受依列卡福/替扎卡福/艾伐卡福治疗后的呼吸结局和曲霉血清学检查
Lung. 2025 Jan 6;203(1):24. doi: 10.1007/s00408-024-00781-4.
5
Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy.囊性纤维化中细菌感染和微生物群的变化概况：在CFTR调节剂治疗时代何时使用抗生素。
Eur Respir Rev. 2024 Dec 4;33(174). doi: 10.1183/16000617.0068-2024. Print 2024 Oct.
6
Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.囊性纤维化跨膜传导调节因子（CFTR）调节剂时代的变应性支气管肺曲霉病（ABPA）
J Fungi (Basel). 2024 Sep 18;10(9):656. doi: 10.3390/jof10090656.
7
Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis.宏基因组学在囊性纤维化患者呼吸真菌组中的应用。
Mycopathologia. 2024 Sep 12;189(5):82. doi: 10.1007/s11046-024-00887-6.
8
Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces in Cystic Fibrosis.依列卡福妥/替扎卡福妥/依伐卡托显著降低囊性纤维化患者的（相关指标，原文未明确具体所指）。
Am J Respir Crit Care Med. 2024 Nov 1;210(9):1155-1158. doi: 10.1164/rccm.202406-1128RL.
9
Allergic bronchopulmonary aspergillosis as an initial manifestation of cystic fibrosis: Diagnostic and therapeutic implications in the era of CFTR modulators.变应性支气管肺曲霉菌病作为囊性纤维化的初始表现：CFTR调节剂时代的诊断和治疗意义
J Allergy Clin Immunol Glob. 2024 Jun 27;3(4):100294. doi: 10.1016/j.jacig.2024.100294. eCollection 2024 Nov.
10
Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden.卢美他尼/依伐卡托对囊性纤维化患者呼吸道细菌和真菌病原体的影响：瑞典一项前瞻性多中心队列研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241254090. doi: 10.1177/17534666241254090.